Literature DB >> 12631592

Automated quantification of apoptosis after neoadjuvant chemotherapy for breast cancer: early assessment predicts clinical response.

Darren W Davis1, Thomas A Buchholz, Kenneth R Hess, Aysegul A Sahin, Vincente Valero, David J McConkey.   

Abstract

PURPOSE: A large body of evidence implicates apoptosis in the effects of cancer chemotherapeutic agents on tumor cells in vitro and tumor xenografts in vivo, but the predictive value of apoptosis as an early marker for clinical response in cancer patients remains unclear. EXPERIMENTAL
DESIGN: We developed an automated, laser scanning cytometer-based method to quantify the percentage of tumor cells containing DNA fragmentation characteristic of apoptosis in tumor sections. We measured levels of apoptosis in a panel of 15 matched, 18-gauge core breast cancer biopsies obtained before and 48 h after neoadjuvant therapy with docetaxel plus doxorubicin or paclitaxel as part of two prospective clinical trials.
RESULTS: The results revealed a strongly significant (P = 0.0023) association between chemotherapy-induced apoptosis and pathological response.
CONCLUSIONS: If the results can be validated in a larger patient cohort, the method could be used to "tailor" therapy to optimize benefit in a patient-specific fashion.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12631592

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  15 in total

1.  Roundness variation in JPEG images affects the automated process of nuclear immunohistochemical quantification: correction with a linear regression model.

Authors:  Carlos López; Joaquín Jaén Martinez; Marylène Lejeune; Patricia Escrivà; Maria T Salvadó; Lluis E Pons; Tomás Alvaro; Jordi Baucells; Marcial García-Rojo; Xavier Cugat; Ramón Bosch
Journal:  Histochem Cell Biol       Date:  2009-08-04       Impact factor: 4.304

2.  A marker of homologous recombination predicts pathologic complete response to neoadjuvant chemotherapy in primary breast cancer.

Authors:  Monika Graeser; Afshan McCarthy; Christopher J Lord; Kay Savage; Margaret Hills; Janine Salter; Nicholas Orr; Marina Parton; Ian E Smith; Jorge S Reis-Filho; Mitch Dowsett; Alan Ashworth; Nicholas C Turner
Journal:  Clin Cancer Res       Date:  2010-08-27       Impact factor: 12.531

3.  Curcumin potentiates the antitumor effects of gemcitabine in an orthotopic model of human bladder cancer through suppression of proliferative and angiogenic biomarkers.

Authors:  Sheeja T Tharakan; Teruo Inamoto; Bokyung Sung; Bharat B Aggarwal; Ashish M Kamat
Journal:  Biochem Pharmacol       Date:  2009-08-12       Impact factor: 5.858

4.  Positron emission tomography imaging of drug-induced tumor apoptosis with a caspase-3/7 specific [18F]-labeled isatin sulfonamide.

Authors:  Quang-Dé Nguyen; Graham Smith; Matthias Glaser; Meg Perumal; Erik Arstad; Eric O Aboagye
Journal:  Proc Natl Acad Sci U S A       Date:  2009-09-03       Impact factor: 11.205

5.  Activation of the mTOR pathway by low levels of xenoestrogens in breast epithelial cells from high-risk women.

Authors:  William H Goodson; Maria Gloria Luciani; S Aejaz Sayeed; Ian M Jaffee; Dan H Moore; Shanaz H Dairkee
Journal:  Carcinogenesis       Date:  2011-09-01       Impact factor: 4.944

Review 6.  Paradoxical roles of caspase-3 in regulating cell survival, proliferation, and tumorigenesis.

Authors:  Ebrahim Eskandari; Connie J Eaves
Journal:  J Cell Biol       Date:  2022-05-12       Impact factor: 8.077

7.  APOMAB, a La-specific monoclonal antibody, detects the apoptotic tumor response to life-prolonging and DNA-damaging chemotherapy.

Authors:  Fares Al-Ejeh; Jocelyn M Darby; Chris Tsopelas; Douglas Smyth; Jim Manavis; Michael P Brown
Journal:  PLoS One       Date:  2009-02-27       Impact factor: 3.240

8.  Chemotherapy synergizes with radioimmunotherapy targeting La autoantigen in tumors.

Authors:  Fares Al-Ejeh; Jocelyn M Darby; Michael P Brown
Journal:  PLoS One       Date:  2009-02-27       Impact factor: 3.240

Review 9.  Surrogate markers in antiangiogenesis clinical trials.

Authors:  D W Davis; D J McConkey; J L Abbruzzese; R S Herbst
Journal:  Br J Cancer       Date:  2003-07-07       Impact factor: 7.640

10.  Early changes in apoptosis and proliferation following primary chemotherapy for breast cancer.

Authors:  C D Archer; M Parton; I E Smith; P A Ellis; J Salter; S Ashley; G Gui; N Sacks; S R Ebbs; W Allum; N Nasiri; M Dowsett
Journal:  Br J Cancer       Date:  2003-09-15       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.